Breathing muscle training for adults with heart failure
Tests breathing muscle training in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Inspiratory Muscle Training in HFpEF
Key facts
- Where
- Rochester, United StatesSee the site
Where in United States
- Mayo Clinic in RochesterRochester, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mayo Clinic
- Trial code
- NCT06510231
- Record updated
- 7 August 2026
- Original description
This study is being done to determine how inspiratory muscle training impacts inspiratory muscle function during exercise in heart failure patients.Read full original descriptionShow less
Inspiratory Muscle Training in Heart Failure With Preserved Ejection Fraction
This study is being done to determine how inspiratory muscle training impacts inspiratory muscle function during exercise in heart failure patients.
Inclusion: ≥18 yrs of age; Receiving SGLT2 inhibitors and spironolactone (and beta-blocker use for HFpEF patients with hypertension) for >3 months; NYHA symptoms I-III; Body mass index ≤40 kg/m2; Currently non-smokers with <20 pack year history; Able to exercise (i.e. without significant orthopedic limitations or musculoskeletal disorders limiting their ability to exercise).
Exclusion: Second or third degree heart block; Uremia, history of allergy to iodides; Peripheral artery disease; Ruptured eardrum or any other condition of the ear; History of spontaneous pneumothorax or osteoporosis with a history of rib fractures; History of lidocaine allergy; For individuals agreeing to undergo dual energy x-ray absorptiometry (DEXA) scanning for measurement of body composition as part of their study visit, additional exclusion criteria apply: recently administered gastrointestinal contrast or radionuclides; severe degenerative changes or fracture deformity in measurement areas; or inability to attain correct position and/or remain motionless for the measurement period; Alanine transaminase and/or aspartate transaminase greater than 2 times the upper limit of normal (via clinical record within the past 6 months); Sustained ventricular tachycardia and/or ventricular fibrillation within 21 days of visit 1; Body mass index >40 kg/m2; Current smokers and/or smoking history >20 pack years; Pregnant women (testing will be done by research team if requested); Glomerular filtration rate of <30 mL/min/1.73m2 (initial screen via clinical record within the past 6 months and this will be assessed on Visit 1); Individuals who are not able to engage in exercise; Asthmatic patients with a low symptom perception and suffer frequency, severe exacerbations or with an abnormally low perception of dyspnea.